Clinical and pharmacokinetic study of oral NK611, a new podophyllotoxin derivative

Cancer Chemotherapy and Pharmacology

Volumn 38, Issue 6, 1996, Pages 541-547

  Pagani, O ^a   Zucchetti, M ^b   Sessa, C ^a   De Jong, J ^a   D'Incalci, M ^b   De Fusco, M ^b   Kaeser Frohlich A ^c   Hanauske, A ^d   Cavalli, F ^a  

^a OSPEDALE SAN GIOVANNI   (Switzerland)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c ASTA MEDICA AG   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Bioavailability; Pharmacokinetics; Podophyllotoxin derivative

Indexed keywords

2'' DEOXY 2'' (DIMETHYLAMINO)ETOPOSIDE; DRUG METABOLITE; ETOPOSIDE; PODOPHYLLOTOXIN DERIVATIVE;

ADULT; AGED; ARTICLE; BIOAVAILABILITY; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG URINE LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; MELANOMA; NAUSEA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; THROMBOCYTOPENIA; ULTRAVIOLET SPECTROPHOTOMETRY;

ADMINISTRATION, ORAL; ADRENAL GLAND NEOPLASMS; ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BONE NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; PODOPHYLLOTOXIN; THROMBOCYTOPENIA;

EID: 0029823029     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050524     Document Type: Article

References (16)

1. Asta Medica (1993) Investigator's drug brochure: NK611. Asta Medica, Frankfurt
2. De Fusco M, D'Incalci M, Gentili D, Reichert S, Zucchetti M (1995) High-performance liquid chromatographic assay for the determination of the novel etoposide derivative dimethylaminoetoposide (NK611) and its metabolites in urine of cancer patients. J Chromatogr B664: 409
3. D'Incalci M, Farina P, Sessa C, et al (1982) Pharmacokinetics of VP16-213 given by different administration methods. Cancer Chemother Pharmacol 7:141
4. Ekimoto H, Okamoto K, Nakamori K, Takahashi K, Takeuchi T (1990) Antitumor and pharmacokinetic properties of a novel water-soluble etoposide analog (NK611) (abstract 2668). Proc Am Assoc Cancer Res 31:449
5. Ekimoto H, Okamoto K, Kusama K, Mashiba H, Takeuchi T (1992) Treatment schedule dependency of antitumor effect of NK611, a novel water-soluble analog of etoposide, on human tumor xenografts. (abstract 2606) Proc Am Assoc Cancer Res 33:436
6. Ekimoto H, Okamoto K, Maruyama S, Mashiba H, Nakamori K, Takeuchi T (1994) Preclinical characterization of NK611, a novel water soluble etoposide analog (abstract 159). Ann Oncol 5 [Suppl 5] : 98
7. Fukuoka M, Takada M, Negoro S, Furuse K, Niitani H (1994) Phase 1 and pharmacokinetic study of NK611 (dimethylaminoetoposide): daily 1-hour intravenous infusion for 5 days-Cooperative Study Group of NK611 in Japan (abstract 471). Ann Oncol 5 [Suppl 5] : 193
8. Hande KR, Krozely MG, Greco FA, et al (1993) Bioavailability of low-dose oral etoposide. J Clin Oncol 11:374
9. Harvey VJ, Slevin ML, Joel SP, et al (1985) Variable bioavailability following repeated oral doses of etoposide. Eur J Cancer Clin Oncol 21:1315
10. Miller AB, Hoogstraten B, Staquet M, et al (1981) Reporting results of cancer treatment. Cancer 47:207
11. Rassmann I, Schilling T, Schrödel H, Kaeser-Fröhlich A, Burk K, Rastetter J, Hanauske AR (1995) Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611 using an oral daily administration schedule (abstract 111). Eur J Cancer 31A [Suppl 5]: 527
12. Rassmann I, Schilling T, Mross K, Hüttmann A, Berdel WE, Manegold C, Fiebig HH, Kaeser-Fröhlich A, Burk K, Rastetter J, Hanauske AR (1996) Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611 using an intravenous administration schedule. Onkologie (in press)
13. Rowland M, Tozer TN (1989) Clinical pharmacokinetics, 2nd edn. Lea & Febiger, Philadelphia
14. Sacchi-Landriani G, Guardabasso V, Rocchetti M (1983) NL-FIT: a microcomputer program for non-linear fitting. Comput Programs Biomed 16:35
15. Schilling T, Mross K, Berdel WE, Manegold CH, Fiebig HH (1994) Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611 (abstract 470). Ann Oncol 5 [Suppl 5] : 193
16. Zucchetti M, De Fusco M, Sessa C, Fröhlich A, Reichert S, D'Incalci M (1994) High-performance liquid chromatographic assay for the determination of the novel podophyllotoxin derivative dimethylaminoetoposide (NK611) in human plasma. J Chromatogr B654:97